Ignite Creation Date:
2024-05-06 @ 8:29 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06390748
Status:
COMPLETED
Last Update Posted:
2024-05-29
First Post:
2024-04-21
Brief Title:
Esmolol in Sepsis ManagementEvaluating Immunomodulatory Effects and Impact on Patient Outcomes
Sponsor:
Lin Chen
Organization:
Sichuan Provincial Peoples Hospital
Study Overview
Official Title:
Investigating the Immunomodulatory Effects of Esmolol in Sepsis Management and Its Impact on Patient Outcomes
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate the effectiveness of esmolol a selective β1-adrenergic receptor blocker in modulating immune responses and improving patient outcomes in sepsis
Detailed Description:
The research aimed to investigate the immunomodulatory effects of Esmolol in sepsis treatment A comprehensive study was conducted incorporating both direct experimental assays and data extraction from Electronic Health Records EHR to evaluate physiological and immunological responses in septic patients Specifically Norepinephrine NE levels were measured and CD4CD8 T cells were quantified to assess changes influenced by Esmolol administration Additionally cytokine profiles Procalcitonin PCT levels complete blood counts CBC and routine biochemical functions were monitored through data retrieved from EHR systems providing a broad perspective on patient health and response to treatment This multifaceted approach aimed to determine how Esmolol affects key immune parameters and overall patient outcomes addressing both the direct and systemic impacts of this treatment on septic patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None